Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older at the time of signing the consent form
- You have been diagnosed with a specific type of cancer (adenocarcinoma, squamous cell carcinoma, or mixed type) of the oesophagus (food pipe) or the area where the food pipe meets the stomach, confirmed by a tissue sample
- You are scheduled to receive a combination of radiation therapy and chemotherapy (using drugs called carboplatin and paclitaxel, given weekly) as your planned treatment
- You are willing and able to sign a written consent form agreeing to take part in the trial
- You are able to follow the trial's requirements, including carrying out some measurements yourself at home
Who may not be able to join:
- You have a condition that affects your thinking, understanding, or mental health in a way that would prevent you from giving informed consent or from completing the at-home measurements required by the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rudolf S.N. Fehrmann, MD, PhD, University Medical Center Groningen
Phone: +31503611419
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine the feasibility of at home monitoring in addition to standard of care
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.